MedTrace Logo

Yellow Fever Vaccination Under Low Dose Methotrexate Therapy

NCT02383680 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2015-03-09

No results posted yet for this study

Summary

Travelers (n = 30, 15 taking low-dose methotrexate (MTX), 15 healthy controls (HC), seeking travel advice in one of the following Swiss Travel Centers (Aarau, Basel, Bern, Geneva, Lausanne, Zurich) and who have an indication for yellow fever (YF) vaccination according to the Swiss Federal Office of Public Health's vaccination recommendations are invited to participate in this study. After signing the consent form (i) YF viremia and (ii) anti-YF antibody production in patients taking low-dose MTX and HC will be compared after YF vaccination. It will be analyzed whether the percentage of people with protective antibodies differs between the two groups and (iii) vaccine side effects will be compared between the groups.

Conditions

  • Rheumatic
  • Dermatologic Disorders

Interventions

BIOLOGICAL

Yellow Fever Vaccination

The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.

Sponsors & Collaborators

  • Swiss Tropical & Public Health Institute

    collaborator OTHER

  • Kantonsspital Aarau

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    collaborator OTHER

  • University Hospital, Geneva

    collaborator OTHER

  • Centre Hospitalier Universitaire Vaudois

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Christoph Hatz, Prof MD · University of Zurich, Epidemiolgy, Biostatistics and Prevention Institute

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-01-31
Completion
2016-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02383680 on ClinicalTrials.gov